JP2018030795A - 脳機能改善組成物 - Google Patents
脳機能改善組成物 Download PDFInfo
- Publication number
- JP2018030795A JP2018030795A JP2016162585A JP2016162585A JP2018030795A JP 2018030795 A JP2018030795 A JP 2018030795A JP 2016162585 A JP2016162585 A JP 2016162585A JP 2016162585 A JP2016162585 A JP 2016162585A JP 2018030795 A JP2018030795 A JP 2018030795A
- Authority
- JP
- Japan
- Prior art keywords
- brain function
- composition
- chewing
- weight
- improving composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 142
- 210000004556 brain Anatomy 0.000 title claims abstract description 25
- 230000001055 chewing effect Effects 0.000 claims abstract description 61
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 48
- 238000010521 absorption reaction Methods 0.000 claims abstract description 46
- 230000004913 activation Effects 0.000 claims abstract description 11
- 230000037406 food intake Effects 0.000 claims abstract description 10
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- 230000003925 brain function Effects 0.000 claims description 145
- 210000000214 mouth Anatomy 0.000 claims description 64
- 230000006872 improvement Effects 0.000 claims description 26
- 208000019505 Deglutition disease Diseases 0.000 claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 22
- 230000018984 mastication Effects 0.000 claims description 17
- 238000010077 mastication Methods 0.000 claims description 17
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 11
- 229930003451 Vitamin B1 Natural products 0.000 claims description 11
- 229930003471 Vitamin B2 Natural products 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 11
- 229960000304 folic acid Drugs 0.000 claims description 11
- 235000019152 folic acid Nutrition 0.000 claims description 11
- 239000011724 folic acid Substances 0.000 claims description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims description 11
- 239000011713 pantothenic acid Substances 0.000 claims description 11
- 229960002477 riboflavin Drugs 0.000 claims description 11
- 229960003495 thiamine Drugs 0.000 claims description 11
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 11
- 235000010374 vitamin B1 Nutrition 0.000 claims description 11
- 239000011691 vitamin B1 Substances 0.000 claims description 11
- 235000019164 vitamin B2 Nutrition 0.000 claims description 11
- 239000011716 vitamin B2 Substances 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 8
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 230000003405 preventing effect Effects 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000004877 mucosa Anatomy 0.000 abstract description 5
- 230000031891 intestinal absorption Effects 0.000 abstract description 4
- 210000005178 buccal mucosa Anatomy 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 37
- 230000009747 swallowing Effects 0.000 description 36
- 206010003504 Aspiration Diseases 0.000 description 25
- 235000015110 jellies Nutrition 0.000 description 24
- 239000008274 jelly Substances 0.000 description 24
- 239000003623 enhancer Substances 0.000 description 17
- 235000019640 taste Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 14
- 239000000787 lecithin Substances 0.000 description 14
- 235000010445 lecithin Nutrition 0.000 description 14
- 229940067606 lecithin Drugs 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- 210000003800 pharynx Anatomy 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- 229940124532 absorption promoter Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229940014662 pantothenate Drugs 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 235000011194 food seasoning agent Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 241001274189 Pomatomus saltatrix Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Jellies, Jams, And Syrups (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
Abstract
Description
(2)咀嚼硬度がJISK6253タイプAデュロメータによるゴム硬度値で1〜50であって、表面積が5〜15cm2のグミ状としたこと。
(3)口腔内における非咀嚼状態での溶けきる時間が3分以内であること。
(4)咀嚼硬度が1〜15kN/m2であり、口内付着性が150J/m3以下であり、咀嚼時の口内凝集性が0.1〜0.9であり、表面積が35〜85cm2であるゼリー状としたこと。
(5)口腔内における非咀嚼状態での溶けきる時間が2分以内であること。
(6)前記フォスファチジルコリンによる脳の活性化を助長する補助成分を更に含み、同補助成分は、脳機能改善組成物100重量部あたり、30×10-6〜300×10-3重量部のビタミンCと、0.45×10-6〜300×10-3重量部のビタミンB1と、0.5×10-6〜300×10-3重量部のビタミンB2と、0.081×10-6〜300×10-3重量部の葉酸と、2×10-6〜300×10-3重量部のパントテン酸と、からなること。
(7)嚥下困難化呈味成分として魚油由来のドコサヘキサエン酸又はエイコサペンタエン酸を更に含有し、経口摂取時の口腔内滞留時間を増大させて前記フォスファチジルコリンの舌下からの吸収量を増加させるべく構成したこと。
まず、本実施形態に係るグミ状の脳機能改善組成物として、基本となるGu-a01の調製を行った。
次に、上述した基準グミ製剤の調製法に準じ、Gu-a01をベースとして糖類の種類やゲル化剤の種類、賦形剤の量等を適宜調整しつつ、テクスチャや表面積の異なる複数のグミ製剤Gu-a02〜Gu-a12の調製を行った。調製した各グミ製剤のテクスチャ試験結果は以下の通りであった。
・Gu-a02(口腔内付着性50、口腔内凝集性1.0、ゴム硬度50、表面積15)
・Gu-a03(口腔内付着性300、口腔内凝集性1.0、ゴム硬度50、表面積15)
・Gu-a04(口腔内付着性200、口腔内凝集性0.5、ゴム硬度50、表面積15)
・Gu-a05(口腔内付着性200、口腔内凝集性0.1、ゴム硬度50、表面積15)
・Gu-a06(口腔内付着性200、口腔内凝集性0.05、ゴム硬度50、表面積15)
・Gu-a07(口腔内付着性200、口腔内凝集性1.0、ゴム硬度60、表面積15)
・Gu-a08(口腔内付着性200、口腔内凝集性1.0、ゴム硬度1、表面積15)
・Gu-a09(口腔内付着性200、口腔内凝集性1.0、ゴム硬度0.5、表面積15)
・Gu-a10(口腔内付着性200、口腔内凝集性1.0、ゴム硬度50、表面積20)
・Gu-a11(口腔内付着性200、口腔内凝集性1.0、ゴム硬度50、表面積5)
・Gu-a12(口腔内付着性200、口腔内凝集性1.0、ゴム硬度50、表面積3)
次に、本実施形態に係るゼリー状の脳機能改善組成物として、基本となるJe-a01の調製を行った。
次に、上述した基準ゼリー製剤の調製法に準じ、Je-a01をベースとして糖類の種類やゲル化剤の種類、水分や賦形剤の量等を適宜調整しつつ、テクスチャや表面積の異なる複数のゼリー製剤Je-a02〜Je-a12の調製を行った。調製した各ゼリー製剤のテクスチャ試験結果は以下の通りであった。
・Je-a02(口腔内付着性50、口腔内凝集性0.9、咀嚼硬度15、表面積85)
・Je-a03(口腔内付着性200、口腔内凝集性0.9、咀嚼硬度15、表面積85)
・Je-a04(口腔内付着性150、口腔内凝集性1.1、咀嚼硬度15、表面積85)
・Je-a05(口腔内付着性150、口腔内凝集性0.1、咀嚼硬度15、表面積85)
・Je-a06(口腔内付着性150、口腔内凝集性0.05、咀嚼硬度15、表面積85)
・Je-a07(口腔内付着性150、口腔内凝集性0.9、咀嚼硬度20、表面積85)
・Je-a08(口腔内付着性150、口腔内凝集性0.9、咀嚼硬度1、表面積85)
・Je-a09(口腔内付着性150、口腔内凝集性0.9、咀嚼硬度0.05、表面積85)
・Je-a10(口腔内付着性150、口腔内凝集性0.9、咀嚼硬度15、表面積95)
・Je-a11(口腔内付着性150、口腔内凝集性0.9、咀嚼硬度15、表面積35)
・Je-a12(口腔内付着性150、口腔内凝集性0.9、咀嚼硬度15、表面積30)
次に、調製したグミ製剤Gu-a01〜Gu-a12、及びゼリー製剤Je-a01〜Je-a12を用い、誤嚥の起こるおそれについて検討を行った。具体的には65〜78歳の被験者10名(男性3名、女性7名)を対象にそれぞれの製剤を摂取させ、飲み込みやすさについて評価させた。誤嚥を起こす不安感があった…1点、ややのどに詰まる感じを受けた…2点、飲み込みに抵抗感を感じる…3点、ふつう…4点、飲み込みに安心感がある…5点として、各製剤毎の評価点の平均を算出した。また、平均点4点以上のものを誤嚥の可能性が低いと判断した。その結果を表1に示す。
次に、前述の誤嚥防止効果の検証試験にて誤嚥防止効果が認められたグミ状又はゼリー状の脳機能改善組成物について、各脳機能改善組成物を摂取した際の被験者の脳波をトポグラフを用いて測定し、主成分であるフォスファチジルコリン(レシチン)を含まない比較用グミ組成物Gu-contや比較用ゼリー組成物Je-contの摂取時と比較して脳機能が改善されているか否かについて検討を行った。
次に、ビタミンC、ビタミンB2、葉酸、パントテン酸塩、ビタミンB1より構成された舌下吸収促進剤の有無による脳機能改善効果の違いについて検討を行った。
次に、グミ状脳機能改善組成物における舌下吸収促進剤の至適添加量について、Gu-b01をベースに検討を行った。
次に、前述の〔8.グミ状脳機能改善組成物における舌下吸収促進剤の至適添加量の検討〕と同様に、ゼリー状脳機能改善組成物における舌下吸収促進剤の至適添加量について、Je-b01をベースに検討を行った。
次に、嚥下困難化呈味成分としてDHAやEPAを用い、嚥下困難化呈味成分の有無による脳機能改善効果の違いについて検討を行った。
Claims (7)
- ゲルマトリクス中に主成分としてのフォスファチジルコリンを含み、経口摂取により脳の活性化を促す脳機能改善組成物であって、咀嚼時の口内付着性を200J/m3以下とし、咀嚼時の口内凝集性を0.1〜1.0とし、表面積を5〜85cm2としたことを特徴とする脳機能改善組成物。
- 咀嚼硬度がJIS K6253タイプAデュロメータによるゴム硬度値で1〜50であって、表面積が5〜15cm2のグミ状としたことを特徴とする請求項1に記載の脳機能改善組成物。
- 口腔内における非咀嚼状態での溶けきる時間が3分以内であることを特徴とする請求項2に記載の脳機能改善組成物。
- 咀嚼硬度が1〜15kN/m2であり、口内付着性が150J/m3以下であり、咀嚼時の口内凝集性が0.1〜0.9であり、表面積が35〜85cm2であるゼリー状としたことを特徴とする請求項1に記載の脳機能改善組成物。
- 口腔内における非咀嚼状態での溶けきる時間が2分以内であることを特徴とする請求項4に記載の脳機能改善組成物。
- 前記フォスファチジルコリンによる脳の活性化を助長する補助成分を更に含み、
同補助成分は、脳機能改善組成物100重量部あたり、30×10-6〜300×10-3重量部のビタミンCと、0.45×10-6〜300×10-3重量部のビタミンB1と、0.5×10-6〜300×10-3重量部のビタミンB2と、0.081×10-6〜300×10-3重量部の葉酸と、2×10-6〜300×10-3重量部のパントテン酸と、からなることを特徴とする請求項1〜5いずれか1項に記載の脳機能改善組成物。 - 嚥下困難化呈味成分として魚油由来のドコサヘキサエン酸又はエイコサペンタエン酸を更に含有し、経口摂取時の口腔内滞留時間を増大させて前記フォスファチジルコリンの舌下からの吸収量を増加させるべく構成したことを特徴とする請求項6に記載の舌下吸収用の脳機能改善組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016162585A JP6831558B2 (ja) | 2016-08-23 | 2016-08-23 | 脳機能改善組成物 |
CN201710286665.7A CN107753417A (zh) | 2016-08-23 | 2017-04-27 | 脑机能改善组合物 |
HK18106546.6A HK1247088A1 (zh) | 2016-08-23 | 2018-05-21 | 腦機能改善組合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016162585A JP6831558B2 (ja) | 2016-08-23 | 2016-08-23 | 脳機能改善組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018030795A true JP2018030795A (ja) | 2018-03-01 |
JP6831558B2 JP6831558B2 (ja) | 2021-02-17 |
Family
ID=61265150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016162585A Active JP6831558B2 (ja) | 2016-08-23 | 2016-08-23 | 脳機能改善組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6831558B2 (ja) |
CN (1) | CN107753417A (ja) |
HK (1) | HK1247088A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
JP2020180108A (ja) * | 2019-04-24 | 2020-11-05 | 株式会社Hbcフナト | 軽度認知障害を治療又は予防するための組成物 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06237734A (ja) * | 1991-11-06 | 1994-08-30 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性疾患用食品組成物 |
JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
JPH08133984A (ja) * | 1994-11-08 | 1996-05-28 | Yakult Honsha Co Ltd | 脳機能改善剤 |
JPH1118722A (ja) * | 1997-07-03 | 1999-01-26 | Lotte Co Ltd | 記憶力および学習能力を増強させる効果を有する脳機能を活性化する飲食物 |
JPH1180009A (ja) * | 1997-09-12 | 1999-03-23 | Seiwa Yakuhin Kk | 脳機能の改善剤および低下予防剤 |
JP2001521002A (ja) * | 1997-10-24 | 2001-11-06 | コーネル リサーチ ファンデーション インク. | 脳の代謝機能不全のための栄養補充剤 |
JP2004168699A (ja) * | 2002-11-19 | 2004-06-17 | Fancl Corp | 脳機能改善組成物 |
JP2007230870A (ja) * | 2006-02-27 | 2007-09-13 | Unitika Ltd | 脳機能改善剤 |
JP2013018752A (ja) * | 2011-07-13 | 2013-01-31 | Nitto Denko Corp | ゼリー状製剤及びゼリー状製剤の製造方法 |
JP2015524471A (ja) * | 2012-08-07 | 2015-08-24 | ヤンセン ファーマシューティカ エヌ.ベー. | c−FMSキナーゼ阻害剤の調製プロセス |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007028921A (ja) * | 2005-07-22 | 2007-02-08 | Pyuriaporisu Labs Research Co Ltd | 機能性食物 |
CN104026591A (zh) * | 2014-04-04 | 2014-09-10 | 上海英莱腾医药研究有限公司 | 一种含中链甘油三酯的多功能蛋白食品组合物 |
-
2016
- 2016-08-23 JP JP2016162585A patent/JP6831558B2/ja active Active
-
2017
- 2017-04-27 CN CN201710286665.7A patent/CN107753417A/zh active Pending
-
2018
- 2018-05-21 HK HK18106546.6A patent/HK1247088A1/zh unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06237734A (ja) * | 1991-11-06 | 1994-08-30 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性疾患用食品組成物 |
JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
JPH08133984A (ja) * | 1994-11-08 | 1996-05-28 | Yakult Honsha Co Ltd | 脳機能改善剤 |
JPH1118722A (ja) * | 1997-07-03 | 1999-01-26 | Lotte Co Ltd | 記憶力および学習能力を増強させる効果を有する脳機能を活性化する飲食物 |
JPH1180009A (ja) * | 1997-09-12 | 1999-03-23 | Seiwa Yakuhin Kk | 脳機能の改善剤および低下予防剤 |
JP2001521002A (ja) * | 1997-10-24 | 2001-11-06 | コーネル リサーチ ファンデーション インク. | 脳の代謝機能不全のための栄養補充剤 |
JP2004168699A (ja) * | 2002-11-19 | 2004-06-17 | Fancl Corp | 脳機能改善組成物 |
JP2007230870A (ja) * | 2006-02-27 | 2007-09-13 | Unitika Ltd | 脳機能改善剤 |
JP2013018752A (ja) * | 2011-07-13 | 2013-01-31 | Nitto Denko Corp | ゼリー状製剤及びゼリー状製剤の製造方法 |
JP2015524471A (ja) * | 2012-08-07 | 2015-08-24 | ヤンセン ファーマシューティカ エヌ.ベー. | c−FMSキナーゼ阻害剤の調製プロセス |
Non-Patent Citations (1)
Title |
---|
特別用途食品の表示許可等について, JPN6020030005, 2009, ISSN: 0004325025 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
JP2020180108A (ja) * | 2019-04-24 | 2020-11-05 | 株式会社Hbcフナト | 軽度認知障害を治療又は予防するための組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP6831558B2 (ja) | 2021-02-17 |
HK1247088A1 (zh) | 2018-09-21 |
CN107753417A (zh) | 2018-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101325374B1 (ko) | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 | |
EP3045053B1 (en) | Food composition for patients having mastication and swallowing difficulties | |
JP2000279107A (ja) | 非う蝕性易嚥下組成物並びにそれを用いた食品用組成物及び医薬品用組成物 | |
Sun-Waterhouse et al. | Towards human well-being through proper chewing and safe swallowing: multidisciplinary empowerment of food design | |
JP5832081B2 (ja) | 咀嚼嚥下訓練用組成物 | |
JP2008247748A (ja) | 透析患者用栄養組成物 | |
JP5608880B2 (ja) | 嚥下困難者用高栄養ゼリー食品 | |
JP5810605B2 (ja) | 果実含有ハードグミキャンディ様構造物 | |
JP6831558B2 (ja) | 脳機能改善組成物 | |
JP5106948B2 (ja) | ペット用経口投与補助剤組成物 | |
JP5699630B2 (ja) | 歯つきの改善されたコラーゲンペプチド高含有キャンディ様構造物 | |
EP1649758B1 (en) | Masticatable capsule and process for producing the same | |
WO2008053984A1 (fr) | Aliment diététique contenant de l'aloès et de l'agar-agar | |
JPH08140628A (ja) | ゲル化食品組成物 | |
JP2007246541A (ja) | 機能性咀嚼物及びその製造方法 | |
JP2021003006A (ja) | 高カロリー栄養組成物 | |
JP4634757B2 (ja) | 乳化液状経腸栄養剤 | |
US20090291121A1 (en) | Capsule and coated capsules as a delivery system for dietary supplements and therapeutic materials | |
CN109090319A (zh) | 乳矿物盐压片糖果 | |
JP2011136945A (ja) | 皮脂分泌抑制剤及びそれを用いた飲食物及び組成物 | |
JP4840379B2 (ja) | 易嚥下性豆腐様ゲル状食品 | |
JP5587543B2 (ja) | グルコサミンを含有する経口投与用固形製剤 | |
JP2015166328A (ja) | チュアブル錠 | |
KR0129409B1 (ko) | 츄잉 연질정제의 제조방법 | |
JP2023165175A (ja) | 咀嚼機能維持向上又は唾液分泌促進用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6831558 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |